
With patients buying gray-market peptides, HHS’s draft policy aims to reunite prescribers, patients, and pharmacists around these emerging products.
The year 2026 has brought a stark paradox to American pharmacy practice, and it’s affecting the most sought-after prescription drugs on the market.
Although the supply chain for glucagon-like peptide-1 (GLP-1) blockbusters like semaglutide and tirzepatide has stabilized and shortages have resolved, the parallel economy of compounded alternatives remains highly active, leaving pharmacists on the front lines of safety and regulatory battles.1,2






